This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
KROS vs. EXAS: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
KROS vs. EXAS: Which Stock Is the Better Value Option?
Will Reblozyl Enable BMY to Offset the Impact of Generic Competition?
by Ekta Bagri
Reblozyl sales surged 35% in Q1 for BMY, but a failed phase III study clouds expansion plans amid stiff anemia drug competition.
RCKT Stock Up on FDA's RMAT Tag to Gene Therapy for Heart Failure
by Zacks Equity Research
Rocket Pharmaceuticals jumps 16.8% as FDA grants RMAT status to RP-A601 on positive phase I heart disease data.
FDA Advisory Panel Votes Against Approval of GSK's Blenrep Combo
by Zacks Equity Research
GSK stock falls as an FDA panel votes against its Blenrep combo, casting doubt on U.S. approval hopes.
KRYS Begins Dosing With Gene Therapy in Rare Eye Disease, Stock Up
by Zacks Equity Research
Krystal Biotech climbs after dosing begins in a phase I/II trial for KB801, a gene therapy eye drop targeting neurotrophic keratitis.
RYTM Stock Rises on Upbeat Acquired Hypothalamic Obesity Study Data
by Zacks Equity Research
Rhythm Pharmaceuticals jumps 36.6% after its oral drug bivamelagon shows strong BMI and hunger reductions in a phase II study in acquired hypothalamic obesity.
Keros Therapeutics, Inc. (KROS) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Keros Therapeutics (KROS) delivered earnings and revenue surprises of 36,300% and 149.64%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Syndax Pharmaceuticals (SNDX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Syndax (SNDX) delivered earnings and revenue surprises of 5.77% and 36.69%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Implied Volatility Surging for Keros Therapeutics Stock Options
by Zacks Equity Research
Investors need to pay close attention to KROS stock based on the movements in the options market lately.
KROS Initiates Exploring Strategic Alternatives, Stock Gains 18.5%
by Zacks Equity Research
The stock rallies 18.5% after Keros initiates a strategic review process exploring alternatives, including a potential sale of the business.
Wall Street Analysts Think Keros Therapeutics (KROS) Could Surge 156.99%: Read This Before Placing a Bet
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 157% in Keros Therapeutics (KROS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Wall Street Analysts Believe Keros Therapeutics (KROS) Could Rally 153.67%: Here's is How to Trade
by Zacks Equity Research
The mean of analysts' price targets for Keros Therapeutics (KROS) points to a 153.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Keros Therapeutics, Inc. (KROS) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Keros Therapeutics (KROS) delivered earnings and revenue surprises of -22.58% and 97.11%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Keros Therapeutics Stock Plunges 81% in 3 Months: Here's Why
by Zacks Equity Research
KROS stock crashes 81% in three months after dosing with cibotercept was halted in a phase II lung disease study due to adverse pericardial effusion events.
Keros Therapeutics (KROS) Soars 5.1%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Keros Therapeutics (KROS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Down -36.23% in 4 Weeks, Here's Why Keros Therapeutics (KROS) Looks Ripe for a Turnaround
by Zacks Equity Research
The heavy selling pressure might have exhausted for Keros Therapeutics (KROS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Here's Why Keros Therapeutics (KROS) is Poised for a Turnaround After Losing -39.17% in 4 Weeks
by Zacks Equity Research
Keros Therapeutics (KROS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Keros Therapeutics, Inc. (KROS) is on the Move, Here's Why the Trend Could be Sustainable
by Zacks Equity Research
Keros Therapeutics, Inc. (KROS) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Does Keros Therapeutics, Inc. (KROS) Have the Potential to Rally 35.66% as Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for Keros Therapeutics, Inc. (KROS) points to a 35.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Recent Price Trend in Keros Therapeutics, Inc. (KROS) is Your Friend, Here's Why
by Zacks Equity Research
Keros Therapeutics, Inc. (KROS) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Wall Street Analysts Predict a 45.35% Upside in Keros Therapeutics, Inc. (KROS): Here's What You Should Know
by Zacks Equity Research
The mean of analysts' price targets for Keros Therapeutics, Inc. (KROS) points to a 45.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Keros Therapeutics, Inc. (KROS) Is a Great Choice for 'Trend' Investors, Here's Why
by Zacks Equity Research
Keros Therapeutics, Inc. (KROS) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Keros Therapeutics, Inc. (KROS) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
How Much Upside is Left in Keros Therapeutics, Inc. (KROS)? Wall Street Analysts Think 57.46%
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 57.5% in Keros Therapeutics, Inc. (KROS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Keros Therapeutics, Inc. (KROS) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Keros Therapeutics, Inc. (KROS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.